Skip to main content

Advertisement

Log in

Correlation of Quantitative Assay of HBsAg and HBV DNA Levels During Chronic HBV Treatment

  • Original Paper
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background and aim Viral load is used for the diagnosis and monitoring the treatment of chronic hepatitis B (CHB). These methods are molecular-based and are expensive. Previous studies suggest that quantitative hepatitis B surface antigen (HBsAg) studied by automated chemiluminescent microparticle immunoassay can be a surrogate marker. In this study, we aimed to investigate whether quantitative HBsAg correlates hepatitis B virus (HBV) DNA levels during CHB treatment. Methods The study included 18 patients (13 male, 5 female, mean age: 33 ± 9 years) with CHB. They were given pegylated interferon ± lamivudine for 52 months and serum samples were obtained in weeks 0, 4, 8, 24, 48, 52, and 76. HBV DNA was measured by TaqMan polymerase chain reaction (PCR; Erasmus MC, University Medical Center, Rotterdam, The Netherlands). Quantitative HBsAg was studied by automated chemiluminescent microparticle immunoassay (Architect HBsAg, Abbott, IL). Results HBV DNA levels were measured as follows: 9.66, 7.69, 7.06, 5.93, 5.89, 5.88, and 7.27 logarithmic genome equivalent/ml, respectively. The corresponding HBsAg quantitation results were 42,888, 31,176, 37,882, 27,277, 28,279, 29,471, and 31,535 IU/ml, respectively. They showed a significant correlation (canonical correlation = 0.85). Conclusions HBsAg studied by automated chemiluminescent microparticle immunoassay correlates with HBV DNA and can be a surrogate marker during the monitoring of the efficacy of HBV treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bowden S (2006) Serological and molecular diagnosis. Semin Liver Dis 26:97–103

    Article  PubMed  CAS  Google Scholar 

  2. Hatzakis A, Magiorkinis E, Haida C (2006) HBV virological assessment. J Hepatol 44(1 Suppl):S71–S76

    Article  PubMed  CAS  Google Scholar 

  3. Servoss JC, Friedman LS (2004) Serologic and molecular diagnosis of hepatitis B virus. Clin Liver Dis 8:267–281

    Article  PubMed  Google Scholar 

  4. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, Dienstag JL, O’Brien C, Tamburro C, Jacobson IM (1990) A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 323:295–301

    PubMed  CAS  Google Scholar 

  5. Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119:312–323

    PubMed  CAS  Google Scholar 

  6. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA (1999) Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256–1263

    Article  PubMed  CAS  Google Scholar 

  7. van Nunen AB, Hansen BE, Suh DJ, Löhr HF, Chemello L, Fontaine H, Heathcote J, Song BC, Janssen HL, de Man RA, Schalm SW (2003) Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52:420–424

    Article  PubMed  Google Scholar 

  8. Feld J, Lee JY, Locarnini S (2003) New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology 38:545–553

    Article  PubMed  CAS  Google Scholar 

  9. Janssen HLA, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TMK, Gerken G, de Man RA, Niesters HGM, Zondervan P, Hansen B, Schalm SW; HBV 99-01 Study Group; Rotterdam Foundation for Liver Research (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123–129

    Article  PubMed  CAS  Google Scholar 

  10. Beard MT, Edwards KA, Curry EL, Marshall DD, Johnson MN (1996) Research methodology. Part IV: understanding canonical correlation analysis. ABNF J 7:11–18

    PubMed  CAS  Google Scholar 

  11. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A (1981) A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1:377–385

    Article  PubMed  CAS  Google Scholar 

  12. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, Iinuma K, Mushahwar IK (2004) Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 115:217–222

    Article  PubMed  CAS  Google Scholar 

  13. Chen CH, Lee CM, Wang JH, Tung HD, Hung CH, Lu SN (2004) Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. Eur J Gastroenterol Hepatol 16:1213–1218

    Article  PubMed  CAS  Google Scholar 

  14. Gibb R, Nimmo GR, O’Loughlin P, Lowe P, Drummond D (2007) Detection of HBsAg mutants in a population with a low prevalence of hepatitis B virus infection. J Med Virol 79:351–355

    Article  PubMed  Google Scholar 

  15. Scheiblauer H, Soboll H, Nick S (2006) Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol 78:S66–S70

    Article  PubMed  CAS  Google Scholar 

  16. Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, Sakaguchi H, Seki S, Shiomi S, Nishiguchi S (2005) Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 75:235–239

    Article  PubMed  CAS  Google Scholar 

  17. Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N (2006) Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol 37:206–212

    Article  PubMed  CAS  Google Scholar 

  18. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ (2007) Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 5:1462–1468

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Resat Ozaras.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ozaras, R., Tabak, F., Tahan, V. et al. Correlation of Quantitative Assay of HBsAg and HBV DNA Levels During Chronic HBV Treatment. Dig Dis Sci 53, 2995–2998 (2008). https://doi.org/10.1007/s10620-008-0263-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-008-0263-5

Keywords

Navigation